Evidence map›Paper›PMID 31615790›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2020

Clinical Factors Associated with Urinary Tract Cancer in Individuals with Lynch Syndrome.

Jonathan W Wischhusen, Chinedu Ukaegbu, Tara G Dhingra, Hajime Uno, Fay Kastrinos, Sapna Syngal, Matthew B Yurgelun

Open access · greenAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jonathan W WischhusenDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Chinedu UkaegbuDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Tara G DhingraDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Hajime UnoDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Fay KastrinosHerbert Irving Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Columbia University Medical Cancer, New York, New York.
Sapna SyngalDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Matthew B YurgelunDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. matthew_yurgelun@dfci.harvard.edu.
Harvard University · US

Funding

Validation and extension of the PREMM Model for mismatch repair gene mutationsR01CA132829 · NCI · DANA-FARBER CANCER INST · PI SYNGAL, SAPNA · 2008 to 2022
$5.6M
The Genetics and Prevention of Gastrointestinal CancersK24CA113433 · NCI · DANA-FARBER CANCER INSTITUTE · PI SYNGAL, SAPNA · 2005 to 2014
$1.7M
Assessment of Inherited Colon Cancer Prediction Models in Diverse PopulationsK07CA151769 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KASTRINOS, FAY · 2010 to 2014
$855k
NCI NIH HHS K07 CA151769NCI NIH HHS K24 CA113433NCI NIH HHS R01 CA132829
6 · The paper itself

Abstract

backgroundLynch syndrome confers markedly increased risks of various malignancies, including urinary tract cancers (UTC; renal pelvis, ureter, bladder, and possibly kidney cancers). It is unknown how to determine which Lynch syndrome carriers are at highest UTC risk. Our aim was to identify clinical factors associated with UTC among Lynch syndrome carriers.

methodsThe study population was a cohort of 52,758 consecutively ascertained individuals undergoing Lynch syndrome testing at a commercial laboratory. Clinical data were obtained from test request forms completed by the ordering provider. Univariate analysis and multivariate logistic regression were performed to identify factors associated with UTC among Lynch syndrome carriers.

resultsCompared with noncarriers, Lynch syndrome carriers were significantly more likely to have had UTC (4.1% vs. 1.2%;

conclusionsSpecific clinical factors can reliably identify Lynch syndrome carriers most likely to be at risk for UTC. IMPACT: A predictable subset of Lynch syndrome carriers may be most likely to benefit from UTC surveillance/prevention.

Indexed as

AdultAge FactorsBiomarkers, TumorColorectal Neoplasms, Hereditary NonpolyposisCross-Sectional StudiesDNA Mismatch RepairEpithelial Cell Adhesion MoleculeFemaleGerm-Line MutationHeterozygoteHumansMaleMedical History TakingMiddle AgedMutS Homolog 2 ProteinReproducibility of ResultsBiomarkers, TumorEPCAM protein, humanEpithelial Cell Adhesion MoleculeMSH2 protein, humanMutS Homolog 2 Protein

Identifiers

PMID31615790
PMCPMC6954282
OpenAlexW2981178652

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.